More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet approximately one-third of epilepsy patients are refractory to AED treatment. Opportunity in this arena has spurred the development of a range of new AEDs targeting drug-resistant epilepsy, particularly highly refractory orphan pediatric subpopulations such as Lennox-Gastaut syndrome, Dravet syndrome, and acute repetitive seizures. In the past two years, six AEDs have been FDA-approved for refractory patients, and one more is on the near-term horizon. Understanding how prescribers perceive and plan to incorporate new brands in epilepsy is critical for developers facing a complicated, highly generic, and increasingly competitive market.

QUESTIONS ANSWERED

  • How do neurologists perceive the clinical profiles of recently launched and emerging brands?
  • How do neurologists currently prescribe or plan to prescribe new brands? How will they be incorporated into the treatment algorithm?
  • What are the top reasons why some neurologists do not prescribe or would refrain from prescribing recently launched or emerging brands?
  • How will the availability of new brands impact current prescribing for the broad epilepsy population, as well as for niche epilepsy subpopulations?

Markets covered: United States.

Primary research: Survey of 98 U.S. neurologists.

Key companies: Aquestive Therapeutics, GW Pharmaceuticals, Neurelis, SK Biopharmaceuticals, UCB, Zogenix.

Key drugs: Epidiolex (CBD), Diacomit (stiripentol), Fintepla (fenfluramine), Xcopri (cenobamate), Nayzilam (intranasal midazolam), Libervant (buccal diazepam), Valtoco (intranasal diazepam).

Table of contents

  • Epilepsy - Special Topics - Epilepsy Special Topics New Treatments In Epilepsy US
    • Special Topics - New Treatments in Epilepsy - US - October 2020

Author(s): Niyati Khetarpal, Ph.D

"Niyati Khetarpal is a business insights analyst on the Central Nervous System, Pain, and Ophthalmology team at Decision Resources Group. In this role, she conducts primary and secondary research to analyze pharmaceutical markets, with a focus on neurology indications, including epilepsy and MS. She also has specific expertise in patent/IP research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope proteins.”


Related Reports

Epilepsy - Landscape & Forecast - Disease Landscape & Forecast

Epilepsy, which afflicts approximately 4.7 million people in the major pharmaceutical markets under study according to DRG epidemiology, is a heterogen...

View Details

Epilepsy | Disease Landscape and Forecast | G7 | 2020

Epilepsy, which afflicts approximately 4.7 million people in the major markets according to DRG epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a...

View Details